A PHASE 2, MULTICOHORT STUDY OF DARATUMUMAB-BASED THERAPIES IN PARTICIPANTS WITH AMYLOID LIGHT CHAIN (AL) AMYLOIDOSIS
- Registry ID
- 54767414AMY2009
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- JANSSEN RESEARCH AND DEVELOPMENT LLC
- Start date
- 2023-06-19
- Last update
- 2022-01-06
Conditions
Related clinical trials
- A PHASE 1B/2 STUDY OF AZD0120 (ALSO KNOWN AS GC012F), A CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY TARGETING CD19 AND B-CELL MATURATION ANTIGEN (BCMA) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY AL AMYLOIDOSIS
- A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF INTRATHECALLY ADMINISTERED ALN-APP IN PATIENTS WITH CEREBRAL AMYLOID ANGIOPATHY (CAA)
- A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF BIRTAMIMAB PLUS STANDARD OF CARE VS. PLACEBO PLUS STANDARD OF CARE IN MAYO STAGE IV SUBJECTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS
- A PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAEL-101 AND PLASMA CELL DYSCRASIA TREATMENT VERSUS PLACEBO AND PLASMA CELL DYSCRASIA TREATMENT IN PLASMA CELL DYSCRASIA TREATMENT-NAÏVE PATIENTS WITH MAYO STAGE IIIA AL AMYLOIDOSIS
- A PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAEL-101 AND PLASMA CELL DYSCRASIA TREATMENT VERSUS PLACEBO AND PLASMA CELL DYSCRASIA TREATMENT IN PLASMA CELL DYSCRASIA TREATMENT-NAÏVE PATIENTS WITH MAYO STAGE IIIB AL AMYLOIDOSIS
- A RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH CYCLOPHOSPHAMIDE, BORTEZOMIB AND DEXAMETHASONE (CYBORD) COMPARED WITH CYBORD ALONE IN NEWLY DIAGNOSED SYSTEMIC AL AMYLOIDOSIS
View on source registry